Oyster Point Pharma Inc

NASDAQ:OYST   1:17:02 PM EDT
7.09
-0.18 (-2.48%)
Products, Earnings Announcements

Oyster Point Pharma Announces Operating Expense Streamlining Plan

Published: 06/28/2022 20:46 GMT
Oyster Point Pharma Inc (OYST) - Oyster Point Pharma Announces Operating Expense Streamlining Plan.
Oyster Point Pharma Inc - Plan Expected to Deliver Expense Savings of Approximately $6-8 Million in Second Half of 2022 and $40-48 Million in 2023.
Oyster Point Pharma Inc - Company Plans to Continue to Drive Launch of Tyrvaya(®) With Approximately 150-200 Field-based Sales Resources.
Oyster Point Pharma Inc - Study Results for Olympia Phase 2 Clinical Trial for Stage 1 Neurotrophic Keratopathy Expected in Q4'22.
Oyster Point Pharma Inc - Total Operating Expenses in 2023 Are Expected to Be Lower Than Total Operating Expenses in 2022.
Revenue is expected to be $7.83 Million
Adjusted EPS is expected to be -$1.50

Next Quarter Revenue Guidance is expected to be $16.18 Million
Next Quarter EPS Guidance is expected to be -$1.21

More details on our Analysts Page.